Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2025
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
C Saura, J Cortés, S Modi, et al.
ESMO Open
|
June 3, 2025
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study
L García-Estévez, A Bardia, H S Rugo, et al.
Breast (Edinburgh, Scotland)
|
June 24, 2016
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
G Curigliano, P Gómez Pardo, F Meric-Bernstam, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 26, 2018
Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial
S A Hurvitz, R G W Quek, N C Turner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2024
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
F André, J Cortés, G Curigliano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2020
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
J K Litton, S A Hurvitz, L A Mina, et al.
ESMO Open
|
May 25, 2024
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
S A Hurvitz, S-B Kim, W-P Chung, et al.
ESMO Open
|
November 30, 2025
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival
J Crown, D Stroyakovskii, D A Yardley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2020
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
C H Barcenas, S A Hurvitz, J A Di Palma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 10, 2024
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3
M P Goetz, M Toi, J Huober, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2025
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
C Saura, J Cortés, S Modi, et al.
ESMO Open
|
June 3, 2025
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study
L García-Estévez, A Bardia, H S Rugo, et al.
Breast (Edinburgh, Scotland)
|
June 24, 2016
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
G Curigliano, P Gómez Pardo, F Meric-Bernstam, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 26, 2018
Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial
S A Hurvitz, R G W Quek, N C Turner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2024
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
F André, J Cortés, G Curigliano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2020
Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial
J K Litton, S A Hurvitz, L A Mina, et al.
ESMO Open
|
May 25, 2024
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
S A Hurvitz, S-B Kim, W-P Chung, et al.
ESMO Open
|
November 30, 2025
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival
J Crown, D Stroyakovskii, D A Yardley, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 29, 2020
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
C H Barcenas, S A Hurvitz, J A Di Palma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 10, 2024
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3
M P Goetz, M Toi, J Huober, et al.
Page
of 3